Loading…
← CockpitCompetitor Analysis › 9989.HK Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class HOpen in the cockpit ↗

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H9989.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

World's largest producer of heparin API, made from pig-intestine mucosa, sold to global drugmakers.

≈ A Chinese heparin-API dominant supplierMomentum strong 62
Mkt cap
$1.78B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$140,770
20-day average traded
Fwd P/E
8.7×
forward earnings
ROIC−WACC
-2.7 pp
WACC 7.8%
Hurdle
-0 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · HKDHK$3.98
1D-1.0%
1W-0.9%
1M+0.5%
3M-8.4%
6M-12.5%
YTD-23.6%
1Y-27.4%
ATR %2.8%
52w lowhigh31.0% off high

What Shenzhen Hepalink Pharmaceutical does

World's largest producer of heparin API, made from pig-intestine mucosa, sold to global drugmakers.

Sells heparin API mainly to drugmakers who make blood thinners, and also its own finished enoxaparin injections, which pay more per unit. These H shares are the Hong Kong listing of the company also quoted as 002399.SZ.

In one line: A Chinese heparin-API dominant supplier.

Products and services

  • Heparin sodium API
  • Low-molecular-weight heparin (LMWH)
  • Finished-dose anticoagulant drugs

Customers

  • Global pharma companies
  • Hospitals in China

Where it sits in the supply chain

  • Pharmaceuticals
  • Active pharmaceutical ingredients
  • Heparin (anticoagulant) API

What could go right

  • Global anticoagulant drug demand

What could go wrong

  • Raw material (hog supply) price swings
  • API price competition

Moat: narrow (scale, regulatory licence, distribution). Controls raw-material (pig mucosa) supply chain and FDA-audited API plants at global scale.

Headquarters: Shenzhen, China · Founded: 1998 · Employees: 2,150

Named competitors

Shenzhen Hepalink Pharmaceutical at a glance

Size Shenzhen Hepalink Pharmaceutical (9989.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.78B, the 435th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.98 on 18 Nov 2026.

Performance Over six months the shares fell 12.5%, against -0.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 1.3% over the last twelve months (peer median +5.9%); the operating margin is 7.8% (peer median 10.0%).

Valuation It trades at 8.7× forward earnings against a peer median of 19.1× (cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.7 points below its cost of capital (7.8% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 1009989.HK 87
Six months, rebased to 100: Shenzhen Hepalink Pharmaceutical against the median of its 20 peers (local-currency closes).

Shenzhen Hepalink Pharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$5.76BHK$5.92BHK$5.72BHK$6.02BHK$8.32B
Revenue growth—+3%-5%-28%—
Gross profitHK$2.20BHK$1.76BHK$1.80BHK$1.88BHK$2.60B
EBITDAn/aHK$961MHK$1.14BHK$138MHK$1.52B
Net incomeHK$227MHK$379MHK$701M-HK$865MHK$846M
Free cash flowHK$2.27BHK$1.75BHK$2.48BHK$29.3M-HK$981M
Capital expenditureHK$121MHK$131MHK$220MHK$492MHK$259M
Total debtHK$3.63BHK$3.31BHK$3.77BHK$6.12BHK$7.26B

Quarterly statements and history in the cockpit →

Shenzhen Hepalink Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%+10%AGIO600664ETON3933301015RAREZYME000028605507NATCOPHARM300573688166MAZEFAEDMP000908300723CAPLIPOINTINDGN9989.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Hepalink Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×600664ETON3933RAREZYME000028NATCOPHARM300573688166FAEDMP300723CAPLIPOINTINDGN9989.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Hepalink Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%600664ETON39333010156881669989.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shenzhen Hepalink Pharmaceutical is the large dot.

Shenzhen Hepalink Pharmaceutical competitors and peer comparison

Head to head with its named competitors (9989.HK vs 002675.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shenzhen Hepalink Pharmaceutical 9989.HK$1.78B-13%-1%8%8.7×-0.4%
Yantai Dongcheng Biochemicals 002675.SZ$1.59B0%-4%15%47.2×6.0%

How Shenzhen Hepalink Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Hepalink Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure9989.HKPeer medianRank in peer set
1-month return+0.5%-0.6%10th highest of 21
6-month return-12.5%-0.8%9th lowest of 21
Distance from 52-week high-31.0%-33.8%10th highest of 21
Revenue growth (TTM)-1.3%+5.9%6th lowest of 21
Operating margin7.8%10.0%11th highest of 21
Forward P/E8.7×19.1×cheapest of 18
Growth the price implies (Req g, 7 yrs)-0.4%5.4%6th least demanding of 16
Growth delivered (Del g)-0.2%+8.2%2nd lowest of 16
Hurdle (Req g minus delivered)-0.2 pp-6.6 pp7th most demanding of 16
ROIC minus cost of capital-2.7 pp+1.2 pp10th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%

Questions

Who are Shenzhen Hepalink Pharmaceutical's main competitors?
Named competitors: Bioiberica (private or unlisted), Yantai Dongcheng Biochemicals (002675.SZ). The cockpit's measured peer set (industry) also includes Agios Pharmaceuticals (AGIO), Harbin Pharmaceutical (600664.SS), Eton Pharmaceuticals (ETON), United Laboratories International (3933.HK), Qingdao Baheal Medical (301015.SZ), Ultragenyx Pharmaceutical (RARE).
Is Shenzhen Hepalink Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 8.7× against a peer median of 19.1×, cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has Shenzhen Hepalink Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -12.5% against -0.8% for the median peer; over one year -27.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.